Brief: Helix Biopharma Reports Q2 Loss Per Share Of C$0.03

Helix Biopharma

18/03/2019 11:56

March 18 (Reuters) - Helix Biopharma Corp  HBP.TO :
    * . ANNOUNCES FISCAL SECOND QUARTER 2019 RESULTS
    * Q2 LOSS PER SHARE C$0.03
    * COMPANY'S LDOS001 CLINICAL STUDY CONTINUES TO FACE PATIENT
ENROLMENT CHALLENGES
    * HELIX BIOPHARMA - EXPECTS TO FILE IND APPLICATION WITH FDA
FOR
STUDY PROTOCOL TARGETING ADVANCED PANCREATIC CANCER PATIENTS
SOMETIME IN APRIL/MAY 2019
    * SOME VENDORS HAVE PLACED COMPANY ON HOLD AND IS IMPACTING
COMPANY'S CLINICAL DEVELOPMENT PROGRAM
    * DOES NOT BELIEVE IT HAS SUFFICIENT LIQUIDITY, OTHERS  TO
MEET
ITS CURRENT OBLIGATIONS TO BE CRITICAL FOR ITS DEVELOPMENT NEEDS

Source text for Eikon:  ID:nGNX7s8Tys 
Further company coverage:  HBP.TO 

 (Reuters.Briefs@thomsonreuters.com)